Boston Scientific's stock has dropped over 43% year-to-date, wiping out years of gains due to lowered guidance and weakness in key segments like WATCHMAN and Urology. Despite this, a new Buy rating has been initiated, citing achievable guidance after a Q1 reset and expected easing of sales comparisons in the second half of the year that could stabilize the stock. Key risks remain, including further guidance cuts and macroeconomic factors slowing procedures. The stock trades in line with peers, and consistent execution with reaffirmed guidance could drive a recovery.
Belo Sun Mining Corp. has begun technical studies on its Volta Grande Gold Project in Pará, Brazil, by engaging G Mining Services for a Technical Gap Analysis (TGA) and appointing Adilson Araújo Laudares as Engineering Director. The TGA will review a...
Jim Cramer highlights that today's stock market is punishing companies that miss expectations more aggressively than during the 1999 dot-com bubble. While the S&P 500 and Nasdaq hit record highs, the market is narrowly focused on artificial intellige...
Boston Scientific Corporation is experiencing share price weakness due to market share losses in electrophysiology and negative sector sentiment. Despite these challenges, the company remains a leader in pulsed field ablation (PFA) and has promising ...
